{"id":451634,"date":"2021-03-05T07:03:34","date_gmt":"2021-03-05T12:03:34","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451634"},"modified":"2021-03-05T07:03:34","modified_gmt":"2021-03-05T12:03:34","slug":"redhill-to-present-at-upcoming-conferences-in-march","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/","title":{"rendered":"RedHill to Present at Upcoming Conferences in March"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">TEL AVIV, Israel<\/span> and <span class=\"xn-location\">RALEIGH, NC<\/span>, <span class=\"xn-chron\">March 5, 2021<\/span> \/PRNewswire\/ &#8212; <a target=\"_blank\" href=\"https:\/\/www.redhillbio.com\/RedHill\/\" rel=\"nofollow noopener noreferrer\">RedHill Biopharma Ltd.<\/a> (Nasdaq: RDHL) (&#8220;RedHill&#8221; or the &#8220;Company&#8221;), a specialty biopharmaceutical company, today announced that it will present at the following upcoming virtual conferences in March: <\/p>\n<div id=\"prni_dvprnejpg5928left\" dir=\"ltr\">\n        <img decoding=\"async\" id=\"prnejpg5928left\" title=\"RedHill Biopharma\" border=\"0\" alt=\"RedHill Biopharma\" align=\"middle\" src=\"https:\/\/mma.prnewswire.com\/media\/1334141\/RedHill_Biopharma_Logo.jpg\" \/>\n      <\/div>\n<p>\n        <b><br \/>\n          <u>Sachs Spring Life Sciences Week (<span class=\"xn-chron\">March 8-11, 2021<\/span>)<\/u><br \/>\n        <\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>14<sup>th<\/sup> Annual European Life Sciences CEO Forum <br \/><\/b><br \/>\n          <b>Presentation:<\/b> Available on-demand from <span class=\"xn-chron\">March 8<\/span><br \/><b>Speaker:<\/b><span class=\"xn-person\">Guy Goldberg<\/span>, Chief Business Officer<\/p>\n<\/li>\n<li>\n          <b>2<sup>nd<\/sup> Annual European HealthTech CEO Forum\u00a0\u00a0 <br \/><\/b><br \/>\n          <b>Panel: <\/b>Pandemic Response Day &#8211; Advanced Therapeutics\u00a0\u00a0 <br \/><b>Date:<\/b><span class=\"xn-chron\">Tuesday, March 9, 2021<\/span>, <span class=\"xn-chron\">13:20 CET<\/span>\/7:20 am EST\u00a0 <br \/><b>Speaker:<\/b><span class=\"xn-person\">Gilead Raday<\/span>, Chief Operating Officer <br \/>Live event <a target=\"_blank\" href=\"https:\/\/www.sachsforum.com\/2ehtf-registration.html\" rel=\"nofollow noopener noreferrer\">registration<\/a> required <\/li>\n<\/ul>\n<p>\n        <b><br \/>\n          <u>Barclays Global Healthcare Conference (<span class=\"xn-chron\">March 9-11, 2021<\/span>) <br \/><\/u><br \/>\n        <\/b><br \/>\n        <b>Presentation and Q&amp;A:<\/b><br \/>\n        <span class=\"xn-chron\">Thursday, March 11, 2021<\/span>, 8:35 am EST\u00a0 <br \/><b>Speaker:<\/b><span class=\"xn-person\">Dror Ben-Asher<\/span>, Chief Executive Officer <\/p>\n<p>\n        <b><br \/>\n          <u>H.C. Wainwright Global Life Sciences Conference (<span class=\"xn-chron\">March 9-10, 2021<\/span>) <br \/><\/u><br \/>\n        <\/b><br \/>\n        <b>Presentation: <\/b>Available for conference attendees from March 9\u00a0 <br \/><b>Speaker:<\/b><span class=\"xn-person\">Guy Goldberg<\/span>, Chief Business Officer<\/p>\n<p>\n        <b><br \/>\n          <u>33<sup>rd<\/sup> Annual Roth Conference (<span class=\"xn-chron\">March 15-17, 2021<\/span>) <br \/><\/u><br \/>\n        <\/b><br \/>\n        <b>Presentation:<\/b> Available on-demand from March 15\u00a0\u00a0 <br \/><b>Speaker:<\/b><span class=\"xn-person\">Guy Goldberg<\/span>, Chief Business Officer<\/p>\n<p>\n        <b><br \/>\n          <u>BIO-Europe Spring Digital Conference (<span class=\"xn-chron\">March 22-25, 2021<\/span>) <br \/><\/u><br \/>\n        <\/b><br \/>\n        <b>Presentation: <\/b>Available on-demand from <span class=\"xn-chron\">March 22<\/span><br \/><b>Speaker: <\/b><span class=\"xn-person\">Adi Frish<\/span>, Chief Corporate &amp; Business Development Officer<\/p>\n<p>The webcasts will be available for 30 days on the Company&#8217;s website: <a target=\"_blank\" href=\"https:\/\/ir.redhillbio.com\/\" rel=\"nofollow noopener noreferrer\">https:\/\/ir.redhillbio.com<\/a>.<\/p>\n<p>\n        <b>About RedHill Biopharma\u00a0\u00a0 \u00a0 <\/b>\n      <\/p>\n<p>RedHill Biopharma Ltd. (Nasdaq: <a target=\"_blank\" href=\"https:\/\/finance.yahoo.com\/quote\/RDHL?p=RDHL&amp;.tsrc=fin-srch\" rel=\"nofollow noopener noreferrer\">RDHL<\/a>) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, <b>Movantik<sup>\u00ae <\/sup><\/b>for opioid-induced constipation in adults<sup><sup>[1]<\/sup><\/sup>, <b>Talicia<sup>\u00ae<\/sup><\/b>for the treatment of <i>Helicobacter pylori (H. pylori)<\/i> infection in adults<sup><sup>[2]<\/sup><\/sup>, and <b>Aemcolo<sup>\u00ae<\/sup><\/b> for the treatment of travelers&#8217; diarrhea in adults<sup><sup>[3]<\/sup><\/sup>. RedHill&#8217;s key clinical late-stage development programs include: (i) <b>RHB-204<\/b>,\u00a0with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) <b>opaganib (Yeliva<sup>\u00ae<\/sup>, <\/b><b>ABC294640)<\/b>, a first<b>&#8211;<\/b>in<b>&#8211;<\/b>class SK2 selective inhibitor targeting multiple indications with positive Phase 2 COVID-19 data and an ongoing Phase 2\/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) <b>RHB-107 (upamostat)<\/b>, a serine protease inhibitor in a U.S. Phase 2\/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) <b>RHB-104<\/b>, with positive results from a first Phase 3 study for Crohn&#8217;s disease; (v) <b>RHB-102<\/b><b>(Bekinda<sup>\u00ae<\/sup>)<\/b>, with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) <b>RHB<\/b>&#8211;<b>106<\/b>, an encapsulated bowel preparation. More information about the Company is available at <a target=\"_blank\" href=\"http:\/\/www.redhillbio.com\/\" rel=\"nofollow noopener noreferrer\">www.redhillbio.com<\/a> \/ <a target=\"_blank\" href=\"https:\/\/twitter.com\/RedHillBio\" rel=\"nofollow noopener noreferrer\">https:\/\/twitter.com\/RedHillBio<\/a>. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <b><\/p>\n<p><\/b><\/p>\n<p>\n        <i>This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;estimates,&#8221; &#8220;aims,&#8221; &#8220;believes,&#8221; &#8220;hopes,&#8221; &#8220;potential&#8221; or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company&#8217;s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company&#8217;s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company&#8217;s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company&#8217;s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company&#8217;s therapeutic candidates and Talicia<sup>\u00ae<\/sup>; (v) the Company&#8217;s ability to successfully commercialize and promote Movantik<sup>\u00ae<\/sup>, Talicia<sup>\u00ae<\/sup> and Aemcolo<sup>\u00ae<\/sup>; (vi) the Company&#8217;s ability to establish and maintain corporate collaborations; (vii) the Company&#8217;s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build and sustain its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company&#8217;s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company&#8217;s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and commercial products and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company&#8217;s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse events using investigative drugs under the Company&#8217;s Expanded Access Program; and (xiv) competition from other companies and technologies within the Company&#8217;s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company&#8217;s filings with the Securities and Exchange Commission (SEC), including the Company&#8217;s Annual Report on Form 20-F filed with the SEC on <span class=\"xn-chron\">March 4, 2020<\/span>. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.<\/i>\n      <\/p>\n<p>\n        <b>References: <\/b>\n      <\/p>\n<p>[1] Full prescribing information for Movantik<sup>\u00ae<\/sup> (naloxegol) is available at: <a target=\"_blank\" href=\"http:\/\/www.movantik.com\/\" rel=\"nofollow noopener noreferrer\">www.Movantik.com<\/a>. \u00a0\u00a0 <\/p>\n<p>[2] Full prescribing information for Talicia<sup>\u00ae<\/sup> (omeprazole magnesium, amoxicillin and rifabutin) is available at: <a target=\"_blank\" href=\"http:\/\/www.talicia.com\/\" rel=\"nofollow noopener noreferrer\">www.Talicia.com<\/a>. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>[3] Full prescribing information for Aemcolo<sup>\u00ae<\/sup> (rifamycin) is available at: <a target=\"_blank\" href=\"http:\/\/www.aemcolo.com\/\" rel=\"nofollow noopener noreferrer\">www.Aemcolo.com<\/a>.<\/p>\n<p>\u00a0<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Company contact:<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Adi Frish<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Chief Corporate &amp; <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Business Development Officer<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">RedHill Biopharma<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">+972-54-6543-112<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"mailto:adi@redhillbio.com\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">adi@redhillbio.com<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Media contacts:<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>U.S.:<\/b> Bryan Gibbs, Finn Partners<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">+1 212 529 2236<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"mailto:bryan.gibbs@finnpartners.com\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">bryan.gibbs@finnpartners.com<\/a><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>UK:<\/b> Amber Fennell, Consilium<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">+44 (0) 7739 658 783 \u00a0<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"mailto:fennell@consilium-comms.com\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">fennell@consilium-comms.com<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN00301&amp;sd=2021-03-05\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/redhill-to-present-at-upcoming-conferences-in-march-301241415.html\">http:\/\/www.prnewswire.com\/news-releases\/redhill-to-present-at-upcoming-conferences-in-march-301241415.html<\/a><\/p>\n<p>SOURCE  RedHill Biopharma Ltd.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LN00301&amp;Transmission_Id=202103050700PR_NEWS_USPR_____LN00301&amp;DateId=20210305\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire TEL AVIV, Israel and RALEIGH, NC, March 5, 2021 \/PRNewswire\/ &#8212; RedHill Biopharma Ltd. (Nasdaq: RDHL) (&#8220;RedHill&#8221; or the &#8220;Company&#8221;), a specialty biopharmaceutical company, today announced that it will present at the following upcoming virtual conferences in March: Sachs Spring Life Sciences Week (March 8-11, 2021) 14th Annual European Life Sciences CEO Forum Presentation: Available on-demand from March 8Speaker:Guy Goldberg, Chief Business Officer 2nd Annual European HealthTech CEO Forum\u00a0\u00a0 Panel: Pandemic Response Day &#8211; Advanced Therapeutics\u00a0\u00a0 Date:Tuesday, March 9, 2021, 13:20 CET\/7:20 am EST\u00a0 Speaker:Gilead Raday, Chief Operating Officer Live event registration required Barclays Global Healthcare Conference (March 9-11, 2021) Presentation and Q&amp;A: Thursday, March 11, 2021, 8:35 am EST\u00a0 Speaker:Dror Ben-Asher, Chief Executive Officer H.C. Wainwright Global &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;RedHill to Present at Upcoming Conferences in March&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-451634","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>RedHill to Present at Upcoming Conferences in March - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RedHill to Present at Upcoming Conferences in March - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire TEL AVIV, Israel and RALEIGH, NC, March 5, 2021 \/PRNewswire\/ &#8212; RedHill Biopharma Ltd. (Nasdaq: RDHL) (&#8220;RedHill&#8221; or the &#8220;Company&#8221;), a specialty biopharmaceutical company, today announced that it will present at the following upcoming virtual conferences in March: Sachs Spring Life Sciences Week (March 8-11, 2021) 14th Annual European Life Sciences CEO Forum Presentation: Available on-demand from March 8Speaker:Guy Goldberg, Chief Business Officer 2nd Annual European HealthTech CEO Forum\u00a0\u00a0 Panel: Pandemic Response Day &#8211; Advanced Therapeutics\u00a0\u00a0 Date:Tuesday, March 9, 2021, 13:20 CET\/7:20 am EST\u00a0 Speaker:Gilead Raday, Chief Operating Officer Live event registration required Barclays Global Healthcare Conference (March 9-11, 2021) Presentation and Q&amp;A: Thursday, March 11, 2021, 8:35 am EST\u00a0 Speaker:Dror Ben-Asher, Chief Executive Officer H.C. Wainwright Global &hellip; Continue reading &quot;RedHill to Present at Upcoming Conferences in March&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-05T12:03:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1334141\/RedHill_Biopharma_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/redhill-to-present-at-upcoming-conferences-in-march\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/redhill-to-present-at-upcoming-conferences-in-march\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"RedHill to Present at Upcoming Conferences in March\",\"datePublished\":\"2021-03-05T12:03:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/redhill-to-present-at-upcoming-conferences-in-march\\\/\"},\"wordCount\":986,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/redhill-to-present-at-upcoming-conferences-in-march\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1334141\\\/RedHill_Biopharma_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/redhill-to-present-at-upcoming-conferences-in-march\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/redhill-to-present-at-upcoming-conferences-in-march\\\/\",\"name\":\"RedHill to Present at Upcoming Conferences in March - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/redhill-to-present-at-upcoming-conferences-in-march\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/redhill-to-present-at-upcoming-conferences-in-march\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1334141\\\/RedHill_Biopharma_Logo.jpg\",\"datePublished\":\"2021-03-05T12:03:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/redhill-to-present-at-upcoming-conferences-in-march\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/redhill-to-present-at-upcoming-conferences-in-march\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/redhill-to-present-at-upcoming-conferences-in-march\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1334141\\\/RedHill_Biopharma_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1334141\\\/RedHill_Biopharma_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/redhill-to-present-at-upcoming-conferences-in-march\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RedHill to Present at Upcoming Conferences in March\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RedHill to Present at Upcoming Conferences in March - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/","og_locale":"en_US","og_type":"article","og_title":"RedHill to Present at Upcoming Conferences in March - Market Newsdesk","og_description":"PR Newswire TEL AVIV, Israel and RALEIGH, NC, March 5, 2021 \/PRNewswire\/ &#8212; RedHill Biopharma Ltd. (Nasdaq: RDHL) (&#8220;RedHill&#8221; or the &#8220;Company&#8221;), a specialty biopharmaceutical company, today announced that it will present at the following upcoming virtual conferences in March: Sachs Spring Life Sciences Week (March 8-11, 2021) 14th Annual European Life Sciences CEO Forum Presentation: Available on-demand from March 8Speaker:Guy Goldberg, Chief Business Officer 2nd Annual European HealthTech CEO Forum\u00a0\u00a0 Panel: Pandemic Response Day &#8211; Advanced Therapeutics\u00a0\u00a0 Date:Tuesday, March 9, 2021, 13:20 CET\/7:20 am EST\u00a0 Speaker:Gilead Raday, Chief Operating Officer Live event registration required Barclays Global Healthcare Conference (March 9-11, 2021) Presentation and Q&amp;A: Thursday, March 11, 2021, 8:35 am EST\u00a0 Speaker:Dror Ben-Asher, Chief Executive Officer H.C. Wainwright Global &hellip; Continue reading \"RedHill to Present at Upcoming Conferences in March\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-05T12:03:34+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1334141\/RedHill_Biopharma_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"RedHill to Present at Upcoming Conferences in March","datePublished":"2021-03-05T12:03:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/"},"wordCount":986,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1334141\/RedHill_Biopharma_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/","name":"RedHill to Present at Upcoming Conferences in March - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1334141\/RedHill_Biopharma_Logo.jpg","datePublished":"2021-03-05T12:03:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1334141\/RedHill_Biopharma_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1334141\/RedHill_Biopharma_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/redhill-to-present-at-upcoming-conferences-in-march\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"RedHill to Present at Upcoming Conferences in March"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=451634"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451634\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=451634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=451634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=451634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}